Neumora Therapeutics (NASDAQ:NMRA) Receives “Underperform” Rating from Bank of America
Bank of America reiterated their underperform rating on shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) in a research report sent to investors on Wednesday, MarketBeat reports. The brokerage currently has a $1.00 price target on the stock, down from their previous price target of $7.00. NMRA has been the topic of a number of […]
Bank of America reiterated their underperform rating on shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) in a research report sent to investors on Wednesday, MarketBeat reports. The brokerage currently has a $1.00 price target on the stock, down from their previous price target of $7.00. NMRA has been the topic of a number of […]
